TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

RXi Pharmaceuticals Corp (NASDAQ:RXII) Investor Investigation Over Possible Wrongdoing Announced

  • If you purchased shares of RXi Pharmaceuticals Corp (NASDAQ:RXII), you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

Company
RXi Pharmaceuticals Corp
Security

Summary

July 03, 2017 (Shareholders Foundation) - An investigation on behalf of investors in shares of RXi Pharmaceuticals Corp (NASDAQ:RXII) was announced over potential breaches of fiduciary duties by certain officers and directors at RXi Pharmaceuticals.

The investigation by a law firm concerns whether certain RXi Pharmaceuticals officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
Marlborough, MA based RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. RXi Pharmaceuticals Corp (NASDAQ:RXII) shares declined from $2.90 per share in June 2016 to $0.51 per share in May 2017.

Start Monitoring Your Investments